Sarepta Therapeutics IncNASDAQ:SRPT
- LAST PRICE127.9500
- TODAY'S CHANGE (%)-5.3900 (-4.0423%)
- Bid / Lots126.0000/ 1
- Ask / Lots128.0000/ 9
- Open / Previous Close132.0000 / 133.3400
- Day Range
- 52 Week Range
- Volume1,135,069
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SRPT |
|---|---|---|
| 09:32 ET | 15368 | 131.73 |
| 09:33 ET | 3226 | 131 |
| 09:35 ET | 15645 | 130.48 |
| 09:37 ET | 7368 | 130.24 |
| 09:39 ET | 1727 | 130.03 |
| 09:42 ET | 6267 | 129.49 |
| 09:44 ET | 1795 | 129.5103 |
| 09:46 ET | 5160 | 128.56 |
| 09:48 ET | 5294 | 128.3 |
| 09:50 ET | 14826 | 128.03 |
| 09:51 ET | 8386 | 127.1 |
| 09:53 ET | 48848 | 126.275 |
| 09:55 ET | 5133 | 127.95 |
| 09:57 ET | 2044 | 127.61 |
| 10:00 ET | 13824 | 126.8678 |
| 10:02 ET | 4736 | 126.865 |
| 10:04 ET | 6034 | 126.93 |
| 10:06 ET | 3692 | 126.335 |
| 10:08 ET | 5908 | 126.92 |
| 10:09 ET | 5967 | 126.03 |
| 10:11 ET | 5798 | 125.9 |
| 10:13 ET | 3000 | 125.87 |
| 10:15 ET | 5717 | 126.28 |
| 10:18 ET | 6321 | 126.68 |
| 10:20 ET | 12985 | 125.91 |
| 10:22 ET | 3441 | 126.33 |
| 10:24 ET | 4716 | 126.805 |
| 10:26 ET | 1900 | 127.34 |
| 10:27 ET | 3538 | 127.055 |
| 10:29 ET | 3443 | 127.4885 |
| 10:31 ET | 6837 | 127 |
| 10:33 ET | 4450 | 127 |
| 10:36 ET | 2267 | 126.97 |
| 10:38 ET | 4858 | 126.77 |
| 10:40 ET | 4073 | 127.195 |
| 10:42 ET | 750 | 127.13 |
| 10:44 ET | 3351 | 127.09 |
| 10:45 ET | 4448 | 126.825 |
| 10:47 ET | 400 | 127.07 |
| 10:49 ET | 100 | 127.08 |
| 10:51 ET | 6070 | 127.4272 |
| 10:54 ET | 2448 | 127.36 |
| 10:56 ET | 3761 | 127.39 |
| 10:58 ET | 900 | 127.245 |
| 11:00 ET | 2198 | 127.4241 |
| 11:02 ET | 2004 | 127.645 |
| 11:03 ET | 300 | 127.64 |
| 11:05 ET | 1061 | 127.585 |
| 11:07 ET | 300 | 127.42 |
| 11:09 ET | 2441 | 127.42 |
| 11:12 ET | 200 | 127.61 |
| 11:14 ET | 1290 | 127.41 |
| 11:16 ET | 1731 | 127.39 |
| 11:18 ET | 3560 | 127.265 |
| 11:20 ET | 2412 | 127.315 |
| 11:21 ET | 200 | 127.3 |
| 11:23 ET | 200 | 127.2 |
| 11:25 ET | 2100 | 127.26 |
| 11:27 ET | 5246 | 127.035 |
| 11:30 ET | 1900 | 126.8 |
| 11:32 ET | 2763 | 126.8385 |
| 11:34 ET | 1193 | 126.835 |
| 11:36 ET | 1750 | 126.96 |
| 11:38 ET | 200 | 127.19 |
| 11:39 ET | 1600 | 127.365 |
| 11:41 ET | 700 | 127.1968 |
| 11:43 ET | 100 | 127.285 |
| 11:45 ET | 1300 | 127.29 |
| 11:48 ET | 3129 | 127.12 |
| 11:50 ET | 2717 | 126.47 |
| 11:52 ET | 600 | 126.655 |
| 11:54 ET | 4579 | 126.77 |
| 11:56 ET | 500 | 126.605 |
| 11:57 ET | 2149 | 126.73 |
| 11:59 ET | 2693 | 126.96 |
| 12:01 ET | 1300 | 127.22 |
| 12:03 ET | 200 | 127.265 |
| 12:06 ET | 100 | 127.27 |
| 12:08 ET | 700 | 127.33 |
| 12:10 ET | 2000 | 127.2 |
| 12:12 ET | 510 | 127.1775 |
| 12:14 ET | 425 | 127.36 |
| 12:15 ET | 2842 | 127.33 |
| 12:17 ET | 100 | 127.2425 |
| 12:19 ET | 1303 | 127.175 |
| 12:21 ET | 1600 | 127.31 |
| 12:24 ET | 500 | 127.23 |
| 12:26 ET | 100 | 127.16 |
| 12:28 ET | 1100 | 127.13 |
| 12:30 ET | 200 | 127.1 |
| 12:32 ET | 2420 | 126.725 |
| 12:35 ET | 450 | 126.745 |
| 12:37 ET | 2184 | 126.7925 |
| 12:39 ET | 1100 | 126.82 |
| 12:42 ET | 1485 | 127.04 |
| 12:44 ET | 1566 | 127.07 |
| 12:46 ET | 853 | 127.08 |
| 12:48 ET | 300 | 127.08 |
| 12:50 ET | 400 | 127.075 |
| 12:51 ET | 700 | 127.0675 |
| 12:53 ET | 200 | 127.075 |
| 12:57 ET | 1500 | 127 |
| 01:00 ET | 5431 | 127 |
| 01:02 ET | 500 | 126.96 |
| 01:04 ET | 1000 | 126.98 |
| 01:06 ET | 1500 | 127 |
| 01:08 ET | 900 | 127.105 |
| 01:09 ET | 1046 | 127.25 |
| 01:11 ET | 7656 | 127.64 |
| 01:13 ET | 2668 | 127.635 |
| 01:15 ET | 1224 | 127.54 |
| 01:18 ET | 7737 | 128.065 |
| 01:20 ET | 2347 | 128.02 |
| 01:22 ET | 200 | 128 |
| 01:24 ET | 1251 | 127.8075 |
| 01:26 ET | 320 | 127.76 |
| 01:27 ET | 100 | 127.78 |
| 01:29 ET | 2141 | 127.55 |
| 01:31 ET | 4023 | 127.49 |
| 01:33 ET | 1240 | 127.585 |
| 01:36 ET | 1100 | 127.84 |
| 01:38 ET | 1590 | 127.93 |
| 01:40 ET | 600 | 127.76 |
| 01:42 ET | 200 | 127.885 |
| 01:44 ET | 800 | 127.85 |
| 01:45 ET | 1000 | 127.735 |
| 01:47 ET | 100 | 127.61 |
| 01:49 ET | 900 | 127.48 |
| 01:51 ET | 1499 | 127.45 |
| 01:54 ET | 1814 | 127.545 |
| 01:56 ET | 2116 | 127.6325 |
| 01:58 ET | 1000 | 127.7 |
| 02:00 ET | 1000 | 128.05 |
| 02:02 ET | 500 | 128.02 |
| 02:03 ET | 989 | 127.985 |
| 02:05 ET | 700 | 127.92 |
| 02:07 ET | 1000 | 127.53 |
| 02:09 ET | 200 | 127.6425 |
| 02:12 ET | 855 | 127.53 |
| 02:14 ET | 800 | 127.6 |
| 02:16 ET | 2559 | 127.6 |
| 02:18 ET | 4563 | 127.92 |
| 02:20 ET | 1305 | 127.96 |
| 02:21 ET | 1404 | 127.975 |
| 02:23 ET | 1524 | 127.97 |
| 02:25 ET | 600 | 127.875 |
| 02:27 ET | 1920 | 127.82 |
| 02:30 ET | 1406 | 127.71 |
| 02:32 ET | 700 | 127.64 |
| 02:34 ET | 1400 | 127.505 |
| 02:36 ET | 400 | 127.53 |
| 02:38 ET | 700 | 127.5 |
| 02:39 ET | 1224 | 127.615 |
| 02:41 ET | 2681 | 127.86 |
| 02:43 ET | 1316 | 127.98 |
| 02:45 ET | 1707 | 128.145 |
| 02:48 ET | 1660 | 128.045 |
| 02:50 ET | 960 | 127.825 |
| 02:52 ET | 2249 | 127.855 |
| 02:54 ET | 500 | 127.87 |
| 02:56 ET | 800 | 127.72 |
| 02:57 ET | 100 | 127.69 |
| 02:59 ET | 2600 | 127.82 |
| 03:01 ET | 1900 | 127.705 |
| 03:03 ET | 883 | 127.685 |
| 03:06 ET | 710 | 127.59 |
| 03:08 ET | 400 | 127.65 |
| 03:10 ET | 1700 | 127.65 |
| 03:12 ET | 500 | 127.68 |
| 03:14 ET | 916 | 127.655 |
| 03:15 ET | 800 | 127.56 |
| 03:17 ET | 1446 | 127.715 |
| 03:19 ET | 1605 | 128.215 |
| 03:21 ET | 1000 | 128.3 |
| 03:24 ET | 600 | 128.15 |
| 03:28 ET | 1050 | 128.6227 |
| 03:30 ET | 1200 | 128.55 |
| 03:32 ET | 2484 | 128.724 |
| 03:33 ET | 2850 | 128.42 |
| 03:35 ET | 600 | 128.53 |
| 03:37 ET | 3100 | 128.46 |
| 03:39 ET | 2300 | 128.475 |
| 03:42 ET | 4650 | 128.495 |
| 03:44 ET | 2650 | 128.495 |
| 03:46 ET | 5001 | 128.72 |
| 03:48 ET | 1048 | 128.735 |
| 03:50 ET | 1602 | 128.715 |
| 03:51 ET | 7327 | 128.855 |
| 03:53 ET | 2896 | 128.845 |
| 03:55 ET | 17847 | 128.605 |
| 03:57 ET | 17252 | 127.94 |
| 04:00 ET | 178911 | 127.95 |
Nov 29, 2024
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:10PM ET on Friday Nov 29, 2024 by Dow Jones
4:10PM ET on Friday Nov 29, 2024 by Dow Jones
Nov 27, 2024
DJ Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler, from 11:37AM ET on Wednesday Nov 27, 2024 by Dow Jones
11:37AM ET on Wednesday Nov 27, 2024 by Dow JonesDJ Sarepta Therapeutics Is Maintained at Buy by Needham, from 5:49AM ET on Wednesday Nov 27, 2024 by Dow Jones
5:49AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 26, 2024
DJ Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal, from 7:41AM ET on Tuesday Nov 26, 2024 by Dow Jones
7:41AM ET on Tuesday Nov 26, 2024 by Dow JonesSarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sarepta Therapeutics Inc | 12.5B | 105.2x | --- |
Bio-Techne Corp | 11.9B | 80.9x | +11.13% |
Neurocrine Biosciences Inc | 13.0B | 33.7x | +62.04% |
Exelixis Inc | 10.4B | 22.7x | -21.77% |
Medpace Holdings Inc | 10.4B | 30.0x | +35.10% |
Insmed Inc | 13.5B | -13.0x | --- |
Company Information
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Contact Information
- Headquarters
- 215 1st St Ste 415CAMBRIDGE, MA, United States 02142-1213
- Phone
- 617-274-4000
- Fax
- 302-636-5454
Executives
- Independent Chairwoman of the Board
- M. Kathleen Behrens
- President, Chief Executive Officer, Director
- Douglas Ingram
- Chief Financial Officer, Executive Vice President
- Ian Estepan
- Executive Vice President, Chief Scientific Officer, Head of R and D
- Louise Rodino-Klapac
- Executive Vice President, General Counsel, Corporate Secretary
- Ryan Brown
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.2B |
|---|---|
Revenue (TTM) | $1.6B |
Shares Outstanding | 95.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $1.22 |
Book Value | $9.17 |
P/E Ratio | 105.2x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | 76.2x |
Operating Margin | 4.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
